Download MendeleyMechanistic insights into the therapeutic properties of delta opioid receptor.
Bernhard, S.M., Roy Chowdhury, S., Murata, T., Reinl, E.L., Ramos-Gonzalez, N., Denn, E., Appourchaux, K., Inoue, A., England, S.K., Fay, J.F., Majumdar, S., Chanda, B., Che, T.(2026) Sci Adv 12: eaeb6737-eaeb6737
- PubMed: 41880505 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1126/sciadv.aeb6737
- Primary Citation Related Structures:
9PPW, 9PPX, 9PPY, 9PPZ, 9PQ0 - PubMed Abstract:
The delta opioid receptor (DOR) is a promising target for treating pain, anxiety, and depression, yet no DOR-based drugs have reached the clinic. Here, we examine how ligands with varying therapeutic properties modulate DOR function. While full agonists rapidly internalize the receptor, partial agonists show a slower rate of internalization, and antagonists increase cell-surface DOR levels. High-resolution structures of ligand-bound DOR-G i1 complexes, including those with antagonists engaged, reveal key interactions that account for DOR ligand selectivity, potency, and efficacy. Single-molecule fluorescence resonance energy transfer studies show that DOR dynamically samples three distinct states (active, obligate preactive, and inactive), and transition rates are tuned by both ligand efficacy and G protein coupling. The endogenous agonist, met-enkephalin, not only stabilizes the active-state conformation but also catalyzes transitions between the active and inactive states. These results reveal how ligand-specific interactions and receptor dynamics can govern pharmacological profiles and provide a framework for developing DOR-targeted therapeutics.
- Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA.
Organizational Affiliation:
